CMPS COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.…
Industry Peers
Medical Care FacilitiesKey Statistics
About COMPASS Pathways (NASDAQ: CMPS)
›
COMPASS Pathways (NASDAQ: CMPS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 156 employees.
The shares were at 8.650 USD on 19 November 2026, up 51.8% over 52 weeks. Its 52-week range is 4.880 USD to 15.87 USD: the price is 45.5% below the high and 77.3% above the low.
Its market capitalisation is 1.23B USD.
COMPASS Pathways reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 389.59M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 23.31 USD is 169.5% above the current price. The next earnings report is expected on 23 March 2027.